medical conditions 8. covid-19 onset of symptoms began more than 10 days before randomisation 9. currently intubated or intubation is planned within the next 24 hours 10. have known allergies to any of the components used in the formulation of the interventions 11. suspected or proven serious, active bacterial, fungal, viral, or other infection (besides covid-19) that in the opinion of the investigator could constitute a risk when taking intervention 12. have any co-morbidity requiring surgery within \<7 days, or that is considered life- threatening within 29 days 13. have any serious concomitant systemic disease, condition, or disorder that, in the opinion of the investigator, should preclude participation in this study. other exclusions 14. have received treatment with a sars-cov-2 specific monoclonal antibody 15. have participated, within the last 30 days, in a clinical study involving an investigational intervention. if the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed. 16. are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study 17. are pregnant or breast feeding 18. are investigator site personnel directly affiliated with this study

medical conditions 8. covid-19 onset of symptoms began more than 10 days before randomisation 9. currently intubated or intubation is planned within the next 24 hours 10. have known allergies to any of the components used in the formulation of the interventions 11. suspected or proven serious, active bacterial, fungal, viral, or other infection (besides covid-19) that in the opinion of the investigator could constitute a risk when taking intervention 12. have any co-morbidity requiring surgery within \<7 days, or that is considered life- threatening within 29 days 13. have any serious concomitant systemic disease, condition, or disorder that, in the opinion of the investigator, should preclude participation in this study. other exclusions 14. have received treatment with a sars-cov-2 specific monoclonal antibody 15. have participated, within the last 30 days, in a clinical study involving an investigational intervention. if the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed. 16. are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study 17. are pregnant or breast feeding 18. are investigator site personnel directly affiliated with this study

medical conditions covid-19 onset of symptoms began more than 10 days before randomisation currently intubated or intubation is planned within the next 24 hours have known allergies to any of the components used in the formulation of the interventions suspected or proven serious, active bacterial, fungal, viral, or other infection (besides covid-19) that in the opinion of the investigator could constitute a risk when taking intervention have any co-morbidity requiring surgery within <7 days, or that is considered life- threatening within 29 days have any serious concomitant systemic disease, condition, or disorder that, in the opinion of the investigator, should preclude participation in this study. other exclusions have received treatment with a sars-cov-2 specific monoclonal antibody have participated, within the last 30 days, in a clinical study involving an investigational intervention. if the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed. are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study are pregnant or breast feeding are investigator site personnel directly affiliated with this study

medical conditions covid-19 onset of symptoms began more than 10 days before randomisation currently intubated or intubation is planned within the next 24 hours have known allergies to any of the components used in the formulation of the interventions suspected or proven serious, active bacterial, fungal, viral, or other infection (besides covid-19) that in the opinion of the investigator could constitute a risk when taking intervention have any co-morbidity requiring surgery within <7 days, or that is considered life- threatening within 29 days have any serious concomitant systemic disease, condition, or disorder that, in the opinion of the investigator, should preclude participation in this study. other exclusions have received treatment with a sars-cov-2 specific monoclonal antibody have participated, within the last 30 days, in a clinical study involving an investigational intervention. if the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed. are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study are pregnant or breast feeding are investigator site personnel directly affiliated with this study